Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
715 (USA) · Dr. Moreau
consented 2013-02-26
AEs
3
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Moderate DERMATITIS CONTACT — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-07 (study day 71.0); relationship: PROBABLE
moderate
assessed
Moderate DERMATITIS CONTACT — outcome: RECOVERED/RESOLVED; onset 2013-05-07 (study day 71.0); relationship: PROBABLE
mild
assessed
Mild SINUS BRADYCARDIA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-05-13 (study day 77.0); relationship: NONE
Data queries
No data queries.